Anti‐ganglioside antibodies and elevated CSF IgG levels in Guillain‐Barré syndrome (original) (raw)
2006, European Journal of Neurology
Anti‐ganglioside antibody production and dysfunction of blood‐cerebrospinal fluid (CSF) barrier (BCB) are frequent findings in dysimmune neuropathy patients, whereas intrathecal synthesis of immunoglobulins is still a matter of debate. We examined the CSF, immunological and electrophysiological characteristics from a cohort of patients with Guillain‐Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), and from patients with other neurological diseases as control. Thirty‐eight percent of GBS patients and 28% of CIDP patients had detectable serum titers of anti‐ganglioside antibodies, which were associated with a high incidence of motor conduction block and increased F wave latencies. In GBS patients, but not in CIDP or control patients, there was an association between anti‐ganglioside antibodies and increased CSF immunoglobulin‐G (IgG) levels as determined by the IgG index. However, none of the GBS patients had CSF oligoclonal bands (OBs) or indications...
Sign up for access to the world's latest research.
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Related papers
Pathogenicity of anti-ganglioside antibodies in the Guillain-Barré syndrome
Autoimmunity Reviews, 2004
Guillain-Barre syndrome (GBS) is a postinfectious inflammatory polyradiculo-neuropathy characterized bý flaccid paralysis. Antibodies directed against glycolipid structures (gangliosides), which are highly expressed in the peripheral nervous system, are frequently detected in sera from GBS patients. These antibodies interfere with nerve conduction and have been shown to activate phagocytes via IgG receptors (FcgR). These findings support an important role of glycolipid-specific antibodies in the pathogenesis of GBS. ᮊ
Journal of the Neurological Sciences, 2002
Sera from 40 patients with Guillain-Barré syndrome (GBS), including the subtypes acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), acute motor and sensory axonal neuropathy (AMSAN), and Miller Fisher syndrome (MFS) were examined for the presence of anti-ganglioside antibodies using the ganglioside agglutination assay, and the enzyme-linked immunosorbent assay (ELISA). In the ELISA system, sera were tested for IgM and IgG antibodies to GM1, GM2, GD1a, GD1b, GT1b, and GQ1b gangliosides. Antibodies to gangliosides were detected in 21 (53%) of the GBS patients by agglutination assay and in 17 (43%) of the patients by ELISA. Some of the sera reacted with more than one ganglioside. Antibodies were not found in the control sera that were studied. The agglutination assay may be useful for rapid screening of GBS sera for antibodies to multiple gangliosides.
Journal of Neuroimmunology, 2016
Whether patients who have GBS with antibodies to galactocerebroside (Gal-C) and gangliosides (Gal-C-GS-GBS) more often have demyelinating or axonal neuropathy remains controversial. We assessed the electrophysiological data from 16 patients with Gal-C-GS-GBS based on the two established criteria to clarify this issue. In this largest cohort of Gal-C-GS-GBS, eight patients had demyelinating neuropathy and none exhibited axonal neuropathy on either criterion. These data indicated that antibodies to Gal-C, a myelin antigen, might predominantly be associated with demyelinating neuropathy, even in the presence of concomitant antibodies to gangliosides.
International Journal of Immunopathology and Pharmacology, 2009
In the Schwann cells and neuronal plasma membranes the gangliosides are organized in clusters forming complexes of gangliosides in the microdomains termed lipid rafts. We investigated frequency, clinical correlates, fine specificity and pro-inflammatory properties of antibodies to ganglioside complexes (GSCs) in a Guillain Barré syndrome (GBS) population. In 63 patients with different GBS variants we performed an ELISA for antibodies to Campylobacter Jejuni ( C. jejuni), gangliosides and GSCs. We studied the fine specificity of antibodies to GSCs by immunoabsorption study and performed a complement activation assay. Twenty-seven percent of patients had antibodies to GSCs and 71% had antibodies either to single gangliosides or to GSCs. Patients with antibodies to GSCs had more frequent involvement of cranial nerves but did not present more frequent antecedent respiratory, gastrointestinal or C. jejuni infection, did not have a preferential demyelinating or primary axonal GBS variant ...
Mechanisms of Action of Anti‐GM1and Anti‐GQ1bGanglioside Antibodies in Guillain‐Barré Syndrome
The Journal of Infectious Diseases, 1997
Anti-GM 1 and anti-GQ 1b ganglioside antibodies are found in association with acute and chronic peripheral neuropathies, including Guillain-Barré syndrome. They are believed to arise as a result of molecular mimicry with immunogenic microbial polysaccharides. Although anti-ganglioside antibodies are suspected to play a causal role in neuropathy pathogenesis, the details of this have yet to be proven. The approach in this laboratory to solving this issue has been to generate anti-GM 1 and anti-GQ 1b monoclonal antibodies from peripheral blood lymphocytes of affected patients and to study their immunolocalization in peripheral nerve and their electrophysiologic effects in animal models in which peripheral nerve sites are exposed to anti-ganglioside antibodies. These data show that anti-ganglioside antibody-reactive epitopes are widely distributed in peripheral nerve and can cause electrophysiologic abnormalities in a variety of model systems; thus, these data support the view that anti-ganglioside antibody-reactive epitopes may directly contribute to neuropathy pathogenesis.
IOSR Journals , 2019
Introduction: Guillain-Barré syndrome, which is characterized by acute are flexic paralysis with albuminocytologic dissociationis currently the most frequent cause of acuteflaccid paralysis worldwide and constitutes one of the serious emergencies inneurology.Autonomic dysfunction (AD) is a common and important complication in Guillain-Barré syndrome and may be the cause of significant morbidity or death.We conducted the present study with an aim to include antibody testing and autonomic function testing in GBS patients and see if they carried any clinical significance. Aims and Objectives of the Study: 1. To study association between antiganglioside antibodies and outcome inGuillain-Barre Syndrome.2. To study autonomic involvement and antiganglioside antibodies in different subtypes of Guillain-Barre Syndrome. Methods: A sample of 50 subjects fulfilling the inclusion and exclusion criteria were taken and different types of Guillain Barre Syndrome were analysed. Autonomic functioning and Anti-ganglioside antibodies were obtained and their association was assessed. Results: Autonomic dysfunction was seen in 34(68%) patients.IgG antibodies are positive in only 14% of the cases and 44% of AMAN patients.There was no relation between the antiganglioside antibodies and outcome of GBS. Conclusions: Antiganglioside antibodies showed significant association with axonal variants but they didn't show any correlation with their outcome.GT1b antibody was the commonest antiganglioside antibody associated with the axonal variant.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.